November 2015 update - New therapies available to NHS for CLL treatment

 Treatments available to treat CLL in the UK 

With the CLL landscape beginning to change several new treatments have gained approval for treating CLL through the NHS following recent NICE & SMC  recomendation and England Cancer Drugs Fund listing. 

 

England Cancer Drug Fund listing for England availability 

NHS Coices - Cancer Drugs fund website

PDF download - England Cancer Drugs Fund list  

NICE 

 

NICE publish final guidance for idelalisib to treat CLL, moving England and Wales NHS access closer

Configure

NICE publish final guidance  of Idelalisib for treating chronic lymphocytic leukaemia making idlalisib plus rituximab availble to NHS England & Wales. The new treatment offers and option for hard to treat patients living with chronic lymphocytic leukaemia who are untreated and have a 17p deletion or TP53 mutation or for chronic lymphocytic leukaemia  patients that have been treated but have relapsed within 24 months.

NICE technology appraisal guidance [TA359] http://www.nice.org.uk/guidance/TA359

NICE publishes guidance for NHS England & Wales use of obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia

Configure

Obinutuzumab (Gazyvaro), given with a drug called chlorambucil, is recommended as a possible treatment for adults with untreated chronic lymphocytic leukaemia only if:

they have other conditions that make full-dose fludarabine unsuitable for them and
bendamustine is not suitable for them. What does this mean for me?

If you have chronic lymphocytic leukaemia, and your doctor thinks that obinutuzumab (with chlorambucil) is the right treatment, you should be able to have the treatment on the NHS. Technology appraisal guidance [TA343] Published today June 2015

You can access full guidance details on the NICE website here:http://www.nice.org.uk/guidance/ta343

NICE publishes guidance for NHS England & Wales use of ofatumumab in combination with chlorambucil or bendamustine for untreated chronic lymphocytic leukaemia

Configure

Technology appraisal guidance [TA344] Published today June 2015
You can access full guidance details on the NICE website here:http://www.nice.org.uk/guidance/ta344

Ofatumumab (Arzerra) given with a drug called chlorambucil is recommended as a possible treatment for people with untreated chronic lymphocytic leukaemia if treatments containing fludarabine or bendamustine are not suitable.

The Scottish Medicines Consortium (SMC) approves Obinutuzumab (Gazyvaro®) for use within NHS Scotland.  

Dec 2014 - Indication under review: In combination with Chlorambucil, Obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL) and with comorbidities making them unsuitable for full-dose fludarabine based therapy Full guidance PDF download

Ofatumumab (Arzerra®) is accepted for restricted use within NHS Scotland.

Configure

The Scottish Medicines Consortium (SMC) has published advice accepting  Ofatummumab for use in NHS Scotland to treat CLL  Following a full submission assessed under the orphan process

ofatumumab (Arzerra®) is accepted for restricted use within NHS Scotland. 

Idelalisib (Zydelig) has been accepted for restricted use by NHS Scotland.

09 March 2015 - P atients with relapsed CLL who are unsuitable for chemotherapy and treatment naïve patients with 17p deletion or TP53 mutation who are unsuitable for chemo-immunotherapy.

You can read the full guidance &  PDF download on the SMC website  

2016 is set for more change. especially as there many new opportunities planned to come  available through a fast growing list of clinical trials. It is becoming increasingly important to have a consultant with a special interest in CLL on your care team with expert knowledge of these developments and access to latest trials.

 

Latest UK clinical trials listings

CLLSA